Hemiplegic Migraine Prophylaxis
For hemiplegic migraine prophylaxis, start with verapamil or acetazolamide as first-line agents, with flunarizine, lamotrigine, or sodium valproate as alternatives; if these fail, consider anti-CGRP monoclonal antibodies which show emerging evidence of efficacy specifically for reducing aura frequency and disability in this population.
Critical Distinction: Hemiplegic Migraine is NOT Typical Migraine
The standard migraine prophylaxis guidelines 1, 2 do not apply directly to hemiplegic migraine. Triptans are historically contraindicated in hemiplegic migraine for acute treatment due to theoretical stroke concerns, though this remains controversial 3, 4. More importantly, the prophylactic medications proven for typical migraine lack specific evidence in hemiplegic migraine patients, who are systematically excluded from clinical trials 5.
First-Line Prophylactic Options
Based on the available evidence for hemiplegic migraine specifically:
Verapamil (Calcium Channel Blocker)
- Shows promise in clinical practice for hemiplegic migraine 3, 6
- Start low and titrate gradually
- Monitor for bradycardia and constipation
Acetazolamide (Carbonic Anhydrase Inhibitor)
- Supported by empirical evidence in hemiplegic migraine 3, 4
- Particularly useful given the genetic ion channel dysfunction underlying familial forms
- Typical dosing: 250-500 mg daily
Flunarizine
- Recommended as a prophylactic option 3
- Not available in all countries (including the United States)
Second-Line Options
Lamotrigine
- Specifically mentioned for hemiplegic migraine prophylaxis 3, 4
- May be particularly effective for aura symptoms
- Requires slow titration to avoid rash (Stevens-Johnson syndrome risk)
Sodium Valproate
- Evidence supports use in hemiplegic migraine 3
- Absolutely contraindicated in women of childbearing potential due to teratogenicity
Emerging Evidence: Anti-CGRP Monoclonal Antibodies
The most recent and compelling evidence comes from a 2026 systematic review showing anti-CGRP mAbs significantly reduce aura burden in hemiplegic migraine 5:
- Monthly days with aura decreased from median 3 to 0.6 days (p = 0.018)
- MIDAS disability scores decreased from 88 to 28 (p = 0.018)
- 83% of patients achieved >50% reduction in both headache days and aura frequency
- No adverse events reported
- Effective even when traditional prophylactics failed
Individual case reports support galcanezumab efficacy 7, and recent Japanese guidelines acknowledge anti-CGRP mAbs as having potential efficacy 8.
Controversial Agent: Propranolol
Propranolol use in hemiplegic migraine is controversial 3. While one 2024 case report showed success with propranolol preventing recurrent attacks 9, traditional teaching suggests caution with beta-blockers in hemiplegic migraine. However, evidence of actual harm is insufficient to absolutely contraindicate them 3.
Treatment Algorithm
Start with verapamil or acetazolamide as first-line agents based on patient-specific factors (cardiac history, kidney stones, etc.)
If ineffective after 2-3 months, switch to lamotrigine or flunarizine (if available)
If multiple traditional agents fail or are not tolerated, strongly consider anti-CGRP monoclonal antibodies (erenumab, galcanezumab, fremanezumab, or eptinezumab) given the 2026 evidence showing specific benefit for aura reduction 5
Avoid sodium valproate in women of childbearing potential
Consider propranolol cautiously if other options exhausted, despite historical concerns 9, 3
Critical Caveats
- No RCT data exists for any prophylactic treatment specifically in hemiplegic migraine—all recommendations are based on case series, expert opinion, and extrapolation 3, 5
- Attack frequency >2 per month warrants prophylaxis consideration
- Start all medications at low doses and titrate slowly
- Trial period should be 2-3 months before declaring treatment failure
- The motor aura symptoms are often more disabling than the headache itself—focus on reducing aura frequency, not just headache days
- Genetic testing (CACNA1A, ATP1A2, SCN1A, PRRT2) may be considered but does not change acute management 4, 8